ArticleScientific reports2026
Comparative evaluation of HTG and TempO Seq targeted transcriptome profiling methods.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcriptomic profiling is a cornerstone of molecular biology and plays a central role in translational and molecular oncology, where reliable gene expression measurements are essential. Targeted RNA sequencing approaches offer several advantages over whole-transcriptome methods, including high sensitivity, reproducibility, and reduced turnaround time, particularly when working with formalin-fixed paraffin-embedded (FFPE) samples. HTG EdgeSeq HTP has previously addressed these needs; however, the recent discontinuation of this platform has created a technical gap for targeted transcriptome analysis in FFPE specimens. In this study, we perform a systematic technical comparison between HTG EdgeSeq HTP and an analogous targeted platform, TempO-Seq, to assess its suitability as an alternative for research applications in molecular oncology. We analyzed 21 FFPE endometrial cancer samples together with three RNA reference controls derived from cell lines and evaluated concordance across multiple levels of biomarkers, ranging from individual transcripts to complex multi-gene signatures comprising tens to thousands of genes. While single-gene measurements showed limited concordance between platforms, multi-gene biomarkers exhibited substantially higher agreement, indicating that aggregation across multiple probes mitigates platform-specific effects. Overall, our results demonstrate that TempO-Seq provides comparable performance to HTG EdgeSeq HTP at the level of multi-gene biomarkers, supporting its use as a robust alternative for targeted transcriptomic profiling of FFPE samples in molecular oncology research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.